



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 35/02 (2006.01) C07K 14/725 (2006.01)

(21) International Application Number:

PCT/US2022/021997

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/175,997 16 April 2021 (16.04.2021) US
63/209,869 11 June 2021 (11.06.2021) US
63/279,477 15 November 2021 (15.11.2021) US
63/310,492 15 February 2022 (15.02.2022) US

(71) Applicant: KITE PHARMA, INC. [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) Inventors: BELK, Jonathan; 12 Deer Run, Grantham, New Hampshire 03753 (US). CHIVUKULA, Raghavender; 4007 Lambert Way, Hayward, California 94541 (US). DREVER, Matthew; 4417 Kearsarge Court, Concord, California 94518 (US). LIAO, Edward Hai Dhow; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(74) Agent: SANNY, Tony et al.; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TACI/BCMA DUAL BINDING MOLECULES

(57) Abstract: Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the dual TACI-BCMA binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.




Fig. 1